Goal 2: Reduce Human Disease

Submitted by (@mariannes.clancy)

What is the effect of variant genes on AVM development in HHT

Natural genetic variation between individuals can influence the outcome of carrying an HHT mutation. Some gene variants may be protective while others may increase the risk of AVM or telangiectasis. By identifying the variant genes that alter risk of AVM may give clues to the molecular mechanisms of AVM formation and provide new drug targets

Voting

1 net vote
1 up votes
0 down votes
Active

Goal 1: Promote Human Health

Submitted by (@glancast)

Updating level C evidence in Clinical Guidelines

Clinical Guidelines depends on good science. Despite this, only 11% of guidelines that reported level of evidence in 2009, had level of evidence A while 48% had level C. Studies have shown that recommendations based on Level of Evidence C (or their equivalence) are significantly less reliable and may be downgraded, reversed or omitted when better evidence is available. I propose a comprehensive review of ACC/AHA ...more »

Voting

3 net votes
3 up votes
0 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@societyforvascularsurgery)

Animal models of vascular diseases

How can we better model human vascular disease in all its complexity?

­This is key to more effective translation of both diagnostics and therapeutics. Develop improved animal models of vascular diseases including PAD, aneurysm, venous diseases, to facilitate fundamental research and preclinical development.

Voting

2 net votes
3 up votes
1 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@societyforvascularsurgery)

Data from regulatory studies a barrier to evidence-based medicine

Alignment of regulatory, healthcare, and research arms of the government is poor. There is a need to improve the design, quality and usefulness of data from regulatory studies to address major clinical questions and also to facilitate scientific inquiry. This is a barrier to evidence based medicine and improved treatments.

Voting

2 net votes
3 up votes
1 down votes
Active

Goal 3: Advance Translational Research

Submitted by (@k.willard)

Palliative and hospice care for COPD patients

Does palliative care and/or hospice care as practiced across communities improve end-of-life care for COPD – specifically, does it reduce the burden of symptoms, improve HRQoL and satisfaction, reduce utilization in last 6 months of life (i.e. hospital visits, cost, invasive ventilation use, etc), improve the end-of-life experience, and increase the concordance of place of death to expressed patient preferences?

Voting

12 net votes
16 up votes
4 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@dayam0)

Does epinephrine improve outcomes in OHCA

Epinephrine is the primary drug that is used in resuscitation but observational studies and a few small RCT suggest that it improves short term but not long term outcomes. Factors such as timing, dose, quality fo CPR and post-resuscitation care all confound the issue. Large RCTs conducted at multiple centers are desperately needed to address this question.

Voting

1 net vote
3 up votes
2 down votes
Active

Goal 2: Reduce Human Disease

Submitted by (@pandrea)

Interactions between anticoagulant therapy and antiretroviral drugs

Cardiovascular pathology has become a major problem in the management of the HIV-infected patient during the ART era. A large number of HIV patients will receive anticoagulants drugs for secondary prevention of cardiovascular disease. It is therefore critical to understand the interactions between antiretroviral therapy and anticoagulant therapy to safely treat HIV patients.

Voting

2 net votes
5 up votes
3 down votes
Active